International Biotechnology Trust plc (IBT)

London
720.38
+0.38(+0.05%)
  • Volume:
    8,186
  • Bid/Ask:
    718.00/723.00
  • Day's Range:
    718.54 - 723.15

IBT Overview

Prev. Close
720
Day's Range
718.54-723.15
Revenue
67.03M
Open
719.1
52 wk Range
669-862
EPS
1.63
Volume
8,186
Market Cap
297.96M
Dividend (Yield)
28.40
(3.97%)
Average Volume (3m)
84,175
P/E Ratio
4.42
Beta
0.3
1-Year Change
-2.17%
Shares Outstanding
41,383,817
Next Earnings Date
-
What is your sentiment on International Biotechnology Trust plc?
or
Vote to see community's results!

International Biotechnology Trust plc News

  • 3 Biotech Stock Picks
    • ByMorningStar-

    VIDEO: There's more to the biotech sector than the Covid-19 vaccine. International Biotech Trust manager Ailsa Craig has three stock picks

  • Biotech Beyond Covid
    • ByMorningStar-

    VIDEO: Are there still opportunities in the biotech sector now the Covid-19 vaccine roll out is underway? We ask International Biotechnology Trust manager Ailsa Craig

  • Big Pharma, Big Returns?
    • ByMorningStar-

    The UK's biggest pharmaceutical companies are leading the fight against Covid-19, but underwhelming share price performance means investors need to look elsewhere

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellNeutral
Technical IndicatorsStrong BuyBuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellSell

International Biotechnology Trust plc Company Profile

International Biotechnology Trust plc Company Profile

Sector
Financial
Employees
0

International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund’s assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company’s assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of these companies to strategic buyers including major pharmaceutical companies or, in some cases, and through a flotation.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.